myelomas

IMUC is developing cancer‐specific mAb candidates targeting small cell lung cancer, pancreatic, ovarian, colon cancers and multiple myelomas.

SeekingAlpha.com: Home Page 2010

Though living in Maryland, she was advised to consult the experts at Mayo, who have long been at the forefront of refining the diagnostic features of myelomas and testing therapies based on the particular characteristics of patients and their cancers.

NYT > Home Page By JANE E. BRODY 2010

"Proteasome inhibitors are currently being used to treat some types of cancer, including multiple myelomas, although many aspects of this cellular process remain poorly understood," said the paper's senior author, Linda Hendershot, PhD, Genetics and Tumor Cell Biology.

unknown title 2009

"We want to fully understand how endoplasmic reticulum-associated degradation works for antibodies made by plasma cells, so we can design more specific ways to block this process in myelomas."

unknown title 2009

"We want to fully understand how endoplasmic reticulum-associated degradation works for antibodies made by plasma cells, so we can design more specific ways to block this process in myelomas."

unknown title 2009

"We want to fully understand how endoplasmic reticulum-associated degradation works for antibodies made by plasma cells, so we can design more specific ways to block this process in myelomas."

unknown title 2009

"Proteasome inhibitors are currently being used to treat some types of cancer, including multiple myelomas, although many aspects of this cellular process remain poorly understood," said the paper's senior author, Linda Hendershot, PhD, Genetics and Tumor Cell Biology.

unknown title 2009

"Proteasome inhibitors are currently being used to treat some types of cancer, including multiple myelomas, although many aspects of this cellular process remain poorly understood," said the paper's senior author, Linda Hendershot, PhD, Genetics and Tumor Cell Biology.

unknown title 2009

"We want to fully understand how endoplasmic reticulum-associated degradation works for antibodies made by plasma cells, so we can design more specific ways to block this process in myelomas."

unknown title 2009

"Proteasome inhibitors are currently being used to treat some types of cancer, including multiple myelomas, although many aspects of this cellular process remain poorly understood," said the paper's senior author, Linda Hendershot, PhD, Genetics and Tumor Cell Biology.

unknown title 2009